Precision Vaccinations Monovalent, adjuvanted, cell-based inactivated influenza H5N1 vaccine approved for people.
The United States Department of Agriculture’s Agricultural Research Service (APHIS) today announced they approved the emergency use of a highly pathogenic avian influenza (HPAI) vaccine candidate to prevent additional deaths of California Condors.
This vaccine clinical trial will be carried out with the surrogate vultures in North Carolina beginning in May 2023.
As of May 12, 2023, twenty-one Condors have died related to HPAI infections in 2023.
In April 2023, the USDA’s Agricultural Research Service began testing several candidate vaccines.
Since the vaccine has not previously been tested against this strain of the HAPI virus in California Condors, the first step is a test with North American vultures, a similar species.
The authorized vaccine is a killed, inactivated product conditionally licensed by APHIS’ Center for Veterinary Biologics in 2016.